A Non-Randomized, Open-label, Multi-Center, Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer

Inclusion Criteria:

- Pathologically confirmed diagnosis of Stage IIIB (with pleural effusion) or Stage IV
NSCLC with measurable disease by RECIST and evidence of progression

- Availability of tissue for analysis

- ECOG Performance Status 0 or 1

- Adequate organ function as defined in the protocol.

- Must be at least 18 years old and able and willing to sign a written informed consent
document

Exclusion Criteria:

- Poor venous access requiring an indwelling catheter for study drug administration

- Women who are pregnant or lactating

- Ventricular ejection fraction < or = to 55% at baseline

- Any uncontrolled intercurrent illness